#USA #Boston #MEPSGEN #NanoCalibur® Mini #nanoparticle formulation

MEPSGEN Launches the Innovative NanoCalibur® Mini

Introduction
In a significant advancement for drug delivery systems, MEPSGEN US, Inc., a pioneering company in the field, has introduced the NanoCalibur® Mini. This automated system is specifically engineered for small-volume nanoparticle formulation, marking a notable development in early-stage drug discovery and formulation processes.

About the NanoCalibur® Mini
The NanoCalibur® Mini is tailored to formulate lipid nanoparticles (LNPs) and polymeric nanoparticles using volumes ranging from 0.1 to 3 mL. This device is built on MEPSGEN's proprietary microfluidic technology, which ensures precise and stable control over microfluidic flow. This capability allows researchers to achieve rapid and reproducible formulation results, vital for early-stage research that often involves the testing of multiple raw materials and process conditions.

The system features two single-use microfluidic cartridges, accommodating different material volumes for diverse applications, from initial formulation screening to comprehensive preclinical studies. By streamlining the testing process, the NanoCalibur® Mini accelerates development timelines while minimizing reagent consumption and overall experimental costs.

A Seamless Scale-Up Path
The introduction of the Mini marks an extension of MEPSGEN's NanoCalibur® Series, which includes Lab, Pro, and GMP models. This series ensures that users can select the appropriate platform suited for their specific development stage and production scale. Notably, all systems within this series utilize the same microfluidic mixing pattern and structure. This uniformity means that as production scales, the need for process re-optimization is significantly reduced, allowing for consistent nanoparticle quality and reproducibility across batches.

Maintaining Integrity at Scale
One challenge in large-scale nanoparticle production is that high flow rates can generate shear forces that may compromise sensitive payloads like mRNA, resulting in reduced potency. However, the NanoCalibur® Series is designed to maintain stable shear conditions, thereby preserving the integrity of the payload and ensuring consistent nanoparticle quality. This is crucial for therapeutic applications, as it may reduce the required dosage needed for efficacy, addressing issues related to high-dose toxicity typically associated with LNPs.

Promotional Offers to Celebrate the Launch
To celebrate the launch of the NanoCalibur® Mini, MEPSGEN is implementing a series of promotional offers directed at research institutions and companies in the pharmaceutical and biotechnology sectors who are considering adopting the system. Further details will be made available on MEPSGEN’s official website and LinkedIn page in the near future.

Conclusion
With the launch of NanoCalibur® Mini, MEPSGEN aims to enhance support for customers throughout all development phases, starting from early research to GMP manufacturing. According to YongTae Kim, CEO of MEPSGEN, the company is committed to broadening the applications of the NanoCalibur® Series and solidifying its position in the global nanomedicine manufacturing landscape.

About MEPSGEN
MEPSGEN is a biotechnology firm headquartered in Seoul, South Korea, with a branch office in Cambridge, MA. Founded in 2019 by CEO YongTae Kim and Professor Robert Langer from MIT, the company focuses on delivering innovative drug delivery systems through its unique microfluidics technology. The NanoCalibur® Series is pivotal in supporting drug discovery, preclinical research, and GMP manufacturing, while MEPSGEN’s MPS platforms recreate human organ functions to aid in New Approach Methodologies (NAMs), aimed at enhancing drug development success rates. For further information, please visit www.mepsgen.com or contact [email protected]